Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?
Language English Country Czech Republic Media print
Document type Case Reports, Journal Article
- MeSH
- Anticholesteremic Agents adverse effects MeSH
- Antipsychotic Agents adverse effects therapeutic use MeSH
- Benzodiazepines adverse effects therapeutic use MeSH
- Drug Eruptions etiology pathology MeSH
- Drug Interactions MeSH
- Middle Aged MeSH
- Humans MeSH
- Olanzapine MeSH
- Pravastatin adverse effects therapeutic use MeSH
- Risk Factors MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Anticholesteremic Agents MeSH
- Antipsychotic Agents MeSH
- Benzodiazepines MeSH
- Olanzapine MeSH
- Pravastatin MeSH
We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin. The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication. The allergic reaction started to develop after co-administration of pravastatin. Therefore, the combination of atypical antipsychotics with statins should be carefully monitored and the benefits and disadvantages should be balanced.
References provided by Crossref.org